LeMaitre Vascular, Inc.
LeMaitre Vascular, Inc. (LMAT) Stock Competitors & Peer Comparison
See (LMAT) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| LMAT | $110.75 | +2.49% | 2.5B | 43.95 | $2.52 | +0.79% |
| ISRG | $483.46 | +2.39% | 171.7B | 61.28 | $7.89 | N/A |
| BDX | $160.27 | +0.57% | 58.1B | 26.19 | $6.12 | +2.19% |
| BDXA | $59.24 | -2.24% | 55.9B | 21.44 | $2.76 | +2.19% |
| ALC | $77.81 | +0.63% | 37.9B | 39.29 | $1.98 | +0.43% |
| MDLN | $41.69 | +0.54% | 33.9B | 29.20 | $1.43 | N/A |
| RMD | $230.60 | -0.10% | 33.7B | 22.81 | $10.11 | +1.01% |
| WST | $240.34 | +2.07% | 17.3B | 35.45 | $6.78 | +0.36% |
| HOLX | $75.15 | +0.04% | 16.8B | 31.18 | $2.41 | N/A |
| COO | $71.04 | +1.60% | 13.9B | 35.34 | $2.01 | N/A |
Stock Comparison
LMAT vs ISRG Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, ISRG has a market cap of 171.7B. Regarding current trading prices, LMAT is priced at $110.75, while ISRG trades at $483.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas ISRG's P/E ratio is 61.28. In terms of profitability, LMAT's ROE is +0.16%, compared to ISRG's ROE of +0.16%. Regarding short-term risk, LMAT is less volatile compared to ISRG. This indicates potentially lower risk in terms of short-term price fluctuations for LMAT.Check ISRG's competition here
LMAT vs BDX Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, BDX has a market cap of 58.1B. Regarding current trading prices, LMAT is priced at $110.75, while BDX trades at $160.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas BDX's P/E ratio is 26.19. In terms of profitability, LMAT's ROE is +0.16%, compared to BDX's ROE of +0.07%. Regarding short-term risk, LMAT is more volatile compared to BDX. This indicates potentially higher risk in terms of short-term price fluctuations for LMAT.Check BDX's competition here
LMAT vs BDXA Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, LMAT is priced at $110.75, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas BDXA's P/E ratio is 21.44. In terms of profitability, LMAT's ROE is +0.16%, compared to BDXA's ROE of +0.07%. Regarding short-term risk, LMAT is less volatile compared to BDXA. This indicates potentially lower risk in terms of short-term price fluctuations for LMAT.Check BDXA's competition here
LMAT vs ALC Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, ALC has a market cap of 37.9B. Regarding current trading prices, LMAT is priced at $110.75, while ALC trades at $77.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas ALC's P/E ratio is 39.29. In terms of profitability, LMAT's ROE is +0.16%, compared to ALC's ROE of +0.04%. Regarding short-term risk, LMAT is more volatile compared to ALC. This indicates potentially higher risk in terms of short-term price fluctuations for LMAT.Check ALC's competition here
LMAT vs MDLN Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, MDLN has a market cap of 33.9B. Regarding current trading prices, LMAT is priced at $110.75, while MDLN trades at $41.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas MDLN's P/E ratio is 29.20. In terms of profitability, LMAT's ROE is +0.16%, compared to MDLN's ROE of +0.08%. Regarding short-term risk, LMAT is less volatile compared to MDLN. This indicates potentially lower risk in terms of short-term price fluctuations for LMAT.Check MDLN's competition here
LMAT vs RMD Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, RMD has a market cap of 33.7B. Regarding current trading prices, LMAT is priced at $110.75, while RMD trades at $230.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas RMD's P/E ratio is 22.81. In terms of profitability, LMAT's ROE is +0.16%, compared to RMD's ROE of +0.25%. Regarding short-term risk, LMAT is more volatile compared to RMD. This indicates potentially higher risk in terms of short-term price fluctuations for LMAT.Check RMD's competition here
LMAT vs WST Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, WST has a market cap of 17.3B. Regarding current trading prices, LMAT is priced at $110.75, while WST trades at $240.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas WST's P/E ratio is 35.45. In terms of profitability, LMAT's ROE is +0.16%, compared to WST's ROE of +0.17%. Regarding short-term risk, LMAT is less volatile compared to WST. This indicates potentially lower risk in terms of short-term price fluctuations for LMAT.Check WST's competition here
LMAT vs HOLX Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, HOLX has a market cap of 16.8B. Regarding current trading prices, LMAT is priced at $110.75, while HOLX trades at $75.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas HOLX's P/E ratio is 31.18. In terms of profitability, LMAT's ROE is +0.16%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, LMAT is more volatile compared to HOLX. This indicates potentially higher risk in terms of short-term price fluctuations for LMAT.Check HOLX's competition here
LMAT vs COO Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, COO has a market cap of 13.9B. Regarding current trading prices, LMAT is priced at $110.75, while COO trades at $71.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas COO's P/E ratio is 35.34. In terms of profitability, LMAT's ROE is +0.16%, compared to COO's ROE of +0.05%. Regarding short-term risk, LMAT is less volatile compared to COO. This indicates potentially lower risk in terms of short-term price fluctuations for LMAT.Check COO's competition here
LMAT vs BDXB Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, LMAT is priced at $110.75, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas BDXB's P/E ratio is 7.60. In terms of profitability, LMAT's ROE is +0.16%, compared to BDXB's ROE of +0.07%. Regarding short-term risk, LMAT is less volatile compared to BDXB. This indicates potentially lower risk in terms of short-term price fluctuations for LMAT.Check BDXB's competition here
LMAT vs MASI Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, LMAT is priced at $110.75, while MASI trades at $175.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas MASI's P/E ratio is 45.80. In terms of profitability, LMAT's ROE is +0.16%, compared to MASI's ROE of -0.17%. Regarding short-term risk, LMAT is more volatile compared to MASI. This indicates potentially higher risk in terms of short-term price fluctuations for LMAT.Check MASI's competition here
LMAT vs BAX Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, BAX has a market cap of 8.8B. Regarding current trading prices, LMAT is priced at $110.75, while BAX trades at $17.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas BAX's P/E ratio is -9.77. In terms of profitability, LMAT's ROE is +0.16%, compared to BAX's ROE of -0.14%. Regarding short-term risk, LMAT is less volatile compared to BAX. This indicates potentially lower risk in terms of short-term price fluctuations for LMAT.Check BAX's competition here
LMAT vs ATR Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, ATR has a market cap of 8.5B. Regarding current trading prices, LMAT is priced at $110.75, while ATR trades at $129.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas ATR's P/E ratio is 21.90. In terms of profitability, LMAT's ROE is +0.16%, compared to ATR's ROE of +0.15%. Regarding short-term risk, LMAT is more volatile compared to ATR. This indicates potentially higher risk in terms of short-term price fluctuations for LMAT.Check ATR's competition here
LMAT vs RGEN Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, RGEN has a market cap of 6.5B. Regarding current trading prices, LMAT is priced at $110.75, while RGEN trades at $115.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas RGEN's P/E ratio is 133.85. In terms of profitability, LMAT's ROE is +0.16%, compared to RGEN's ROE of +0.02%. Regarding short-term risk, LMAT is less volatile compared to RGEN. This indicates potentially lower risk in terms of short-term price fluctuations for LMAT.Check RGEN's competition here
LMAT vs BLCO Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, BLCO has a market cap of 5.8B. Regarding current trading prices, LMAT is priced at $110.75, while BLCO trades at $16.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas BLCO's P/E ratio is -16.17. In terms of profitability, LMAT's ROE is +0.16%, compared to BLCO's ROE of -0.06%. Regarding short-term risk, LMAT is more volatile compared to BLCO. This indicates potentially higher risk in terms of short-term price fluctuations for LMAT.Check BLCO's competition here
LMAT vs AVTR Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, AVTR has a market cap of 5.2B. Regarding current trading prices, LMAT is priced at $110.75, while AVTR trades at $7.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas AVTR's P/E ratio is -9.76. In terms of profitability, LMAT's ROE is +0.16%, compared to AVTR's ROE of -0.09%. Regarding short-term risk, LMAT is less volatile compared to AVTR. This indicates potentially lower risk in terms of short-term price fluctuations for LMAT.Check AVTR's competition here
LMAT vs TFX Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, TFX has a market cap of 4.8B. Regarding current trading prices, LMAT is priced at $110.75, while TFX trades at $109.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas TFX's P/E ratio is 83.35. In terms of profitability, LMAT's ROE is +0.16%, compared to TFX's ROE of -0.24%. Regarding short-term risk, LMAT is more volatile compared to TFX. This indicates potentially higher risk in terms of short-term price fluctuations for LMAT.Check TFX's competition here
LMAT vs STVN Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, STVN has a market cap of 4.2B. Regarding current trading prices, LMAT is priced at $110.75, while STVN trades at $15.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas STVN's P/E ratio is 26.04. In terms of profitability, LMAT's ROE is +0.16%, compared to STVN's ROE of +0.10%. Regarding short-term risk, LMAT is more volatile compared to STVN. This indicates potentially higher risk in terms of short-term price fluctuations for LMAT.Check STVN's competition here
LMAT vs MMSI Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, MMSI has a market cap of 4.1B. Regarding current trading prices, LMAT is priced at $110.75, while MMSI trades at $69.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas MMSI's P/E ratio is 32.47. In terms of profitability, LMAT's ROE is +0.16%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, LMAT is less volatile compared to MMSI. This indicates potentially lower risk in terms of short-term price fluctuations for LMAT.Check MMSI's competition here
LMAT vs ICUI Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, ICUI has a market cap of 3.1B. Regarding current trading prices, LMAT is priced at $110.75, while ICUI trades at $126.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas ICUI's P/E ratio is 4232.00. In terms of profitability, LMAT's ROE is +0.16%, compared to ICUI's ROE of +0.00%. Regarding short-term risk, LMAT is less volatile compared to ICUI. This indicates potentially lower risk in terms of short-term price fluctuations for LMAT.Check ICUI's competition here
LMAT vs WRBY Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, WRBY has a market cap of 2.8B. Regarding current trading prices, LMAT is priced at $110.75, while WRBY trades at $22.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas WRBY's P/E ratio is 2291.00. In terms of profitability, LMAT's ROE is +0.16%, compared to WRBY's ROE of +0.00%. Regarding short-term risk, LMAT is less volatile compared to WRBY. This indicates potentially lower risk in terms of short-term price fluctuations for LMAT.Check WRBY's competition here
LMAT vs HAE Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, HAE has a market cap of 2.8B. Regarding current trading prices, LMAT is priced at $110.75, while HAE trades at $59.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas HAE's P/E ratio is 16.45. In terms of profitability, LMAT's ROE is +0.16%, compared to HAE's ROE of +0.20%. Regarding short-term risk, LMAT is less volatile compared to HAE. This indicates potentially lower risk in terms of short-term price fluctuations for LMAT.Check HAE's competition here
LMAT vs XRAY Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, XRAY has a market cap of 2.3B. Regarding current trading prices, LMAT is priced at $110.75, while XRAY trades at $11.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas XRAY's P/E ratio is -3.91. In terms of profitability, LMAT's ROE is +0.16%, compared to XRAY's ROE of -0.35%. Regarding short-term risk, LMAT is less volatile compared to XRAY. This indicates potentially lower risk in terms of short-term price fluctuations for LMAT.Check XRAY's competition here
LMAT vs ATRC Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, ATRC has a market cap of 1.5B. Regarding current trading prices, LMAT is priced at $110.75, while ATRC trades at $30.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas ATRC's P/E ratio is -126.83. In terms of profitability, LMAT's ROE is +0.16%, compared to ATRC's ROE of -0.02%. Regarding short-term risk, LMAT is less volatile compared to ATRC. This indicates potentially lower risk in terms of short-term price fluctuations for LMAT.Check ATRC's competition here
LMAT vs PLSE Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, PLSE has a market cap of 1.5B. Regarding current trading prices, LMAT is priced at $110.75, while PLSE trades at $21.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas PLSE's P/E ratio is -20.21. In terms of profitability, LMAT's ROE is +0.16%, compared to PLSE's ROE of -0.73%. Regarding short-term risk, LMAT is less volatile compared to PLSE. This indicates potentially lower risk in terms of short-term price fluctuations for LMAT.Check PLSE's competition here
LMAT vs NVCR Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, NVCR has a market cap of 1.4B. Regarding current trading prices, LMAT is priced at $110.75, while NVCR trades at $12.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas NVCR's P/E ratio is -10.15. In terms of profitability, LMAT's ROE is +0.16%, compared to NVCR's ROE of -0.39%. Regarding short-term risk, LMAT is less volatile compared to NVCR. This indicates potentially lower risk in terms of short-term price fluctuations for LMAT.Check NVCR's competition here
LMAT vs QDEL Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, QDEL has a market cap of 1.2B. Regarding current trading prices, LMAT is priced at $110.75, while QDEL trades at $17.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas QDEL's P/E ratio is -1.06. In terms of profitability, LMAT's ROE is +0.16%, compared to QDEL's ROE of -0.46%. Regarding short-term risk, LMAT is less volatile compared to QDEL. This indicates potentially lower risk in terms of short-term price fluctuations for LMAT.Check QDEL's competition here
LMAT vs KMTS Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, KMTS has a market cap of 1.1B. Regarding current trading prices, LMAT is priced at $110.75, while KMTS trades at $19.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas KMTS's P/E ratio is -4.86. In terms of profitability, LMAT's ROE is +0.16%, compared to KMTS's ROE of -1.89%. Regarding short-term risk, LMAT is less volatile compared to KMTS. This indicates potentially lower risk in terms of short-term price fluctuations for LMAT.Check KMTS's competition here
LMAT vs AZTA Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, AZTA has a market cap of 963.1M. Regarding current trading prices, LMAT is priced at $110.75, while AZTA trades at $20.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas AZTA's P/E ratio is 36.05. In terms of profitability, LMAT's ROE is +0.16%, compared to AZTA's ROE of -0.03%. Regarding short-term risk, LMAT is less volatile compared to AZTA. This indicates potentially lower risk in terms of short-term price fluctuations for LMAT.Check AZTA's competition here
LMAT vs NNNN Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, NNNN has a market cap of 950.7M. Regarding current trading prices, LMAT is priced at $110.75, while NNNN trades at $21.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas NNNN's P/E ratio is 361.00. In terms of profitability, LMAT's ROE is +0.16%, compared to NNNN's ROE of +0.11%. Regarding short-term risk, LMAT is less volatile compared to NNNN. This indicates potentially lower risk in terms of short-term price fluctuations for LMAT.Check NNNN's competition here
LMAT vs BLFS Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, BLFS has a market cap of 921.6M. Regarding current trading prices, LMAT is priced at $110.75, while BLFS trades at $19.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas BLFS's P/E ratio is -76.32. In terms of profitability, LMAT's ROE is +0.16%, compared to BLFS's ROE of -0.03%. Regarding short-term risk, LMAT is less volatile compared to BLFS. This indicates potentially lower risk in terms of short-term price fluctuations for LMAT.Check BLFS's competition here
LMAT vs STAA Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, STAA has a market cap of 895.2M. Regarding current trading prices, LMAT is priced at $110.75, while STAA trades at $18.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas STAA's P/E ratio is -11.16. In terms of profitability, LMAT's ROE is +0.16%, compared to STAA's ROE of -0.23%. Regarding short-term risk, LMAT is less volatile compared to STAA. This indicates potentially lower risk in terms of short-term price fluctuations for LMAT.Check STAA's competition here
LMAT vs ATRI Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, LMAT is priced at $110.75, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas ATRI's P/E ratio is 64.50. In terms of profitability, LMAT's ROE is +0.16%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, LMAT is more volatile compared to ATRI. This indicates potentially higher risk in terms of short-term price fluctuations for LMAT.Check ATRI's competition here
LMAT vs ANGO Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, ANGO has a market cap of 439.8M. Regarding current trading prices, LMAT is priced at $110.75, while ANGO trades at $10.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas ANGO's P/E ratio is -15.93. In terms of profitability, LMAT's ROE is +0.16%, compared to ANGO's ROE of -0.15%. Regarding short-term risk, LMAT is less volatile compared to ANGO. This indicates potentially lower risk in terms of short-term price fluctuations for LMAT.Check ANGO's competition here
LMAT vs OSUR Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, OSUR has a market cap of 228.9M. Regarding current trading prices, LMAT is priced at $110.75, while OSUR trades at $3.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas OSUR's P/E ratio is -3.33. In terms of profitability, LMAT's ROE is +0.16%, compared to OSUR's ROE of -0.19%. Regarding short-term risk, LMAT is less volatile compared to OSUR. This indicates potentially lower risk in terms of short-term price fluctuations for LMAT.Check OSUR's competition here
LMAT vs UTMD Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, UTMD has a market cap of 205M. Regarding current trading prices, LMAT is priced at $110.75, while UTMD trades at $64.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas UTMD's P/E ratio is 18.39. In terms of profitability, LMAT's ROE is +0.16%, compared to UTMD's ROE of +0.10%. Regarding short-term risk, LMAT is more volatile compared to UTMD. This indicates potentially higher risk in terms of short-term price fluctuations for LMAT.Check UTMD's competition here
LMAT vs KRMD Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, KRMD has a market cap of 198.7M. Regarding current trading prices, LMAT is priced at $110.75, while KRMD trades at $4.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas KRMD's P/E ratio is -53.62. In terms of profitability, LMAT's ROE is +0.16%, compared to KRMD's ROE of -0.16%. Regarding short-term risk, LMAT is less volatile compared to KRMD. This indicates potentially lower risk in terms of short-term price fluctuations for LMAT.Check KRMD's competition here
LMAT vs INFU Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, INFU has a market cap of 195M. Regarding current trading prices, LMAT is priced at $110.75, while INFU trades at $9.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas INFU's P/E ratio is 30.94. In terms of profitability, LMAT's ROE is +0.16%, compared to INFU's ROE of +0.12%. Regarding short-term risk, LMAT is less volatile compared to INFU. This indicates potentially lower risk in terms of short-term price fluctuations for LMAT.Check INFU's competition here
LMAT vs STXS Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, STXS has a market cap of 178.7M. Regarding current trading prices, LMAT is priced at $110.75, while STXS trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas STXS's P/E ratio is -6.84. In terms of profitability, LMAT's ROE is +0.16%, compared to STXS's ROE of -1.92%. Regarding short-term risk, LMAT is less volatile compared to STXS. This indicates potentially lower risk in terms of short-term price fluctuations for LMAT.Check STXS's competition here
LMAT vs SMTI Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, SMTI has a market cap of 175.5M. Regarding current trading prices, LMAT is priced at $110.75, while SMTI trades at $19.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas SMTI's P/E ratio is -27.28. In terms of profitability, LMAT's ROE is +0.16%, compared to SMTI's ROE of -1.28%. Regarding short-term risk, LMAT is less volatile compared to SMTI. This indicates potentially lower risk in terms of short-term price fluctuations for LMAT.Check SMTI's competition here
LMAT vs PDEX Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, PDEX has a market cap of 161.9M. Regarding current trading prices, LMAT is priced at $110.75, while PDEX trades at $49.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas PDEX's P/E ratio is 14.55. In terms of profitability, LMAT's ROE is +0.16%, compared to PDEX's ROE of +0.29%. Regarding short-term risk, LMAT is less volatile compared to PDEX. This indicates potentially lower risk in terms of short-term price fluctuations for LMAT.Check PDEX's competition here
LMAT vs MBOT Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, MBOT has a market cap of 124.4M. Regarding current trading prices, LMAT is priced at $110.75, while MBOT trades at $2.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas MBOT's P/E ratio is -6.07. In terms of profitability, LMAT's ROE is +0.16%, compared to MBOT's ROE of -0.37%. Regarding short-term risk, LMAT is less volatile compared to MBOT. This indicates potentially lower risk in terms of short-term price fluctuations for LMAT.Check MBOT's competition here
LMAT vs NYXH Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, NYXH has a market cap of 116.9M. Regarding current trading prices, LMAT is priced at $110.75, while NYXH trades at $3.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas NYXH's P/E ratio is -1.21. In terms of profitability, LMAT's ROE is +0.16%, compared to NYXH's ROE of -1.01%. Regarding short-term risk, LMAT is more volatile compared to NYXH. This indicates potentially higher risk in terms of short-term price fluctuations for LMAT.Check NYXH's competition here
LMAT vs ZTEK Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, ZTEK has a market cap of 65.6M. Regarding current trading prices, LMAT is priced at $110.75, while ZTEK trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas ZTEK's P/E ratio is -10.17. In terms of profitability, LMAT's ROE is +0.16%, compared to ZTEK's ROE of -0.61%. Regarding short-term risk, LMAT is less volatile compared to ZTEK. This indicates potentially lower risk in terms of short-term price fluctuations for LMAT.Check ZTEK's competition here
LMAT vs AKYA Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, LMAT is priced at $110.75, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas AKYA's P/E ratio is -1.34. In terms of profitability, LMAT's ROE is +0.16%, compared to AKYA's ROE of -6.72%. Regarding short-term risk, LMAT is more volatile compared to AKYA. This indicates potentially higher risk in terms of short-term price fluctuations for LMAT.Check AKYA's competition here
LMAT vs DXR Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, DXR has a market cap of 57.1M. Regarding current trading prices, LMAT is priced at $110.75, while DXR trades at $11.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas DXR's P/E ratio is 6.91. In terms of profitability, LMAT's ROE is +0.16%, compared to DXR's ROE of +0.22%. Regarding short-term risk, LMAT is less volatile compared to DXR. This indicates potentially lower risk in terms of short-term price fluctuations for LMAT.Check DXR's competition here
LMAT vs STSS Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, STSS has a market cap of 56.8M. Regarding current trading prices, LMAT is priced at $110.75, while STSS trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas STSS's P/E ratio is N/A. In terms of profitability, LMAT's ROE is +0.16%, compared to STSS's ROE of -0.91%. Regarding short-term risk, LMAT is less volatile compared to STSS. This indicates potentially lower risk in terms of short-term price fluctuations for LMAT.Check STSS's competition here
LMAT vs OMIC Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, LMAT is priced at $110.75, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas OMIC's P/E ratio is -0.58. In terms of profitability, LMAT's ROE is +0.16%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, LMAT is more volatile compared to OMIC. This indicates potentially higher risk in terms of short-term price fluctuations for LMAT.Check OMIC's competition here
LMAT vs IGAP Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, LMAT is priced at $110.75, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas IGAP's P/E ratio is -10.52. In terms of profitability, LMAT's ROE is +0.16%, compared to IGAP's ROE of +1.21%. Regarding short-term risk, LMAT is more volatile compared to IGAP. This indicates potentially higher risk in terms of short-term price fluctuations for LMAT.Check IGAP's competition here
LMAT vs POCI Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, POCI has a market cap of 33M. Regarding current trading prices, LMAT is priced at $110.75, while POCI trades at $4.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas POCI's P/E ratio is -4.59. In terms of profitability, LMAT's ROE is +0.16%, compared to POCI's ROE of -0.61%. Regarding short-term risk, LMAT is less volatile compared to POCI. This indicates potentially lower risk in terms of short-term price fluctuations for LMAT.Check POCI's competition here
LMAT vs NEPH Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, NEPH has a market cap of 31M. Regarding current trading prices, LMAT is priced at $110.75, while NEPH trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas NEPH's P/E ratio is 20.86. In terms of profitability, LMAT's ROE is +0.16%, compared to NEPH's ROE of +0.12%. Regarding short-term risk, LMAT is less volatile compared to NEPH. This indicates potentially lower risk in terms of short-term price fluctuations for LMAT.Check NEPH's competition here
LMAT vs SDC Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, LMAT is priced at $110.75, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas SDC's P/E ratio is -0.03. In terms of profitability, LMAT's ROE is +0.16%, compared to SDC's ROE of -1.96%. Regarding short-term risk, LMAT is less volatile compared to SDC. This indicates potentially lower risk in terms of short-term price fluctuations for LMAT.Check SDC's competition here
LMAT vs EKSO Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, EKSO has a market cap of 27.1M. Regarding current trading prices, LMAT is priced at $110.75, while EKSO trades at $10.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas EKSO's P/E ratio is -2.27. In terms of profitability, LMAT's ROE is +0.16%, compared to EKSO's ROE of -1.11%. Regarding short-term risk, LMAT is less volatile compared to EKSO. This indicates potentially lower risk in terms of short-term price fluctuations for LMAT.Check EKSO's competition here
LMAT vs IVC Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, LMAT is priced at $110.75, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas IVC's P/E ratio is -0.79. In terms of profitability, LMAT's ROE is +0.16%, compared to IVC's ROE of -0.46%. Regarding short-term risk, LMAT is less volatile compared to IVC. This indicates potentially lower risk in terms of short-term price fluctuations for LMAT.Check IVC's competition here
LMAT vs HBIO Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, HBIO has a market cap of 22.4M. Regarding current trading prices, LMAT is priced at $110.75, while HBIO trades at $5.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas HBIO's P/E ratio is -3.91. In terms of profitability, LMAT's ROE is +0.16%, compared to HBIO's ROE of -3.89%. Regarding short-term risk, LMAT is less volatile compared to HBIO. This indicates potentially lower risk in terms of short-term price fluctuations for LMAT.Check HBIO's competition here
LMAT vs MLSS Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, MLSS has a market cap of 21.9M. Regarding current trading prices, LMAT is priced at $110.75, while MLSS trades at $0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas MLSS's P/E ratio is -3.10. In terms of profitability, LMAT's ROE is +0.16%, compared to MLSS's ROE of -1.65%. Regarding short-term risk, LMAT is less volatile compared to MLSS. This indicates potentially lower risk in terms of short-term price fluctuations for LMAT.Check MLSS's competition here
LMAT vs RVP Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, RVP has a market cap of 21.5M. Regarding current trading prices, LMAT is priced at $110.75, while RVP trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas RVP's P/E ratio is -3.26. In terms of profitability, LMAT's ROE is +0.16%, compared to RVP's ROE of -0.08%. Regarding short-term risk, LMAT is less volatile compared to RVP. This indicates potentially lower risk in terms of short-term price fluctuations for LMAT.Check RVP's competition here
LMAT vs ZJYL Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, ZJYL has a market cap of 19.2M. Regarding current trading prices, LMAT is priced at $110.75, while ZJYL trades at $2.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas ZJYL's P/E ratio is 12.25. In terms of profitability, LMAT's ROE is +0.16%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, LMAT is less volatile compared to ZJYL. This indicates potentially lower risk in terms of short-term price fluctuations for LMAT.Check ZJYL's competition here
LMAT vs FEMY Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, FEMY has a market cap of 18.2M. Regarding current trading prices, LMAT is priced at $110.75, while FEMY trades at $0.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas FEMY's P/E ratio is -0.90. In terms of profitability, LMAT's ROE is +0.16%, compared to FEMY's ROE of -7.64%. Regarding short-term risk, LMAT is less volatile compared to FEMY. This indicates potentially lower risk in terms of short-term price fluctuations for LMAT.Check FEMY's competition here
LMAT vs RGNT Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, RGNT has a market cap of 12.5M. Regarding current trading prices, LMAT is priced at $110.75, while RGNT trades at $3.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas RGNT's P/E ratio is -0.13. In terms of profitability, LMAT's ROE is +0.16%, compared to RGNT's ROE of N/A. Regarding short-term risk, LMAT is less volatile compared to RGNT. This indicates potentially lower risk in terms of short-term price fluctuations for LMAT.Check RGNT's competition here
LMAT vs NXGL Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, NXGL has a market cap of 8.6M. Regarding current trading prices, LMAT is priced at $110.75, while NXGL trades at $0.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas NXGL's P/E ratio is -2.19. In terms of profitability, LMAT's ROE is +0.16%, compared to NXGL's ROE of -0.55%. Regarding short-term risk, LMAT is less volatile compared to NXGL. This indicates potentially lower risk in terms of short-term price fluctuations for LMAT.Check NXGL's competition here
LMAT vs LUCY Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, LUCY has a market cap of 5.1M. Regarding current trading prices, LMAT is priced at $110.75, while LUCY trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas LUCY's P/E ratio is -0.55. In terms of profitability, LMAT's ROE is +0.16%, compared to LUCY's ROE of -0.82%. Regarding short-term risk, LMAT is less volatile compared to LUCY. This indicates potentially lower risk in terms of short-term price fluctuations for LMAT.Check LUCY's competition here
LMAT vs NSTG Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, LMAT is priced at $110.75, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas NSTG's P/E ratio is -0.03. In terms of profitability, LMAT's ROE is +0.16%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, LMAT is less volatile compared to NSTG. This indicates potentially lower risk in terms of short-term price fluctuations for LMAT.Check NSTG's competition here
LMAT vs NXGLW Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, NXGLW has a market cap of 3.3M. Regarding current trading prices, LMAT is priced at $110.75, while NXGLW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas NXGLW's P/E ratio is -0.03. In terms of profitability, LMAT's ROE is +0.16%, compared to NXGLW's ROE of -0.55%. Regarding short-term risk, LMAT is less volatile compared to NXGLW. This indicates potentially lower risk in terms of short-term price fluctuations for LMAT.Check NXGLW's competition here
LMAT vs MHUA Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, MHUA has a market cap of 2.7M. Regarding current trading prices, LMAT is priced at $110.75, while MHUA trades at $8.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas MHUA's P/E ratio is 0.28. In terms of profitability, LMAT's ROE is +0.16%, compared to MHUA's ROE of +0.06%. Regarding short-term risk, LMAT is less volatile compared to MHUA. This indicates potentially lower risk in terms of short-term price fluctuations for LMAT.Check MHUA's competition here
LMAT vs GMVD Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, LMAT is priced at $110.75, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas GMVD's P/E ratio is -0.01. In terms of profitability, LMAT's ROE is +0.16%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, LMAT is less volatile compared to GMVD. This indicates potentially lower risk in terms of short-term price fluctuations for LMAT.Check GMVD's competition here
LMAT vs GMVDW Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, LMAT is priced at $110.75, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas GMVDW's P/E ratio is N/A. In terms of profitability, LMAT's ROE is +0.16%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, LMAT is less volatile compared to GMVDW. This indicates potentially lower risk in terms of short-term price fluctuations for LMAT.Check GMVDW's competition here
LMAT vs AVGR Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, LMAT is priced at $110.75, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas AVGR's P/E ratio is -0.05. In terms of profitability, LMAT's ROE is +0.16%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, LMAT is less volatile compared to AVGR. This indicates potentially lower risk in terms of short-term price fluctuations for LMAT.Check AVGR's competition here
LMAT vs POAI Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, POAI has a market cap of 1.2M. Regarding current trading prices, LMAT is priced at $110.75, while POAI trades at $1.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas POAI's P/E ratio is -0.01. In terms of profitability, LMAT's ROE is +0.16%, compared to POAI's ROE of +4.25%. Regarding short-term risk, LMAT is less volatile compared to POAI. This indicates potentially lower risk in terms of short-term price fluctuations for LMAT.Check POAI's competition here
LMAT vs GCTK Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, GCTK has a market cap of 641.1K. Regarding current trading prices, LMAT is priced at $110.75, while GCTK trades at $1.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas GCTK's P/E ratio is N/A. In terms of profitability, LMAT's ROE is +0.16%, compared to GCTK's ROE of -26.59%. Regarding short-term risk, LMAT is less volatile compared to GCTK. This indicates potentially lower risk in terms of short-term price fluctuations for LMAT.Check GCTK's competition here
LMAT vs LUCYW Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, LUCYW has a market cap of 320.5K. Regarding current trading prices, LMAT is priced at $110.75, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas LUCYW's P/E ratio is N/A. In terms of profitability, LMAT's ROE is +0.16%, compared to LUCYW's ROE of -0.82%. Regarding short-term risk, LMAT is less volatile compared to LUCYW. This indicates potentially lower risk in terms of short-term price fluctuations for LMAT.Check LUCYW's competition here
LMAT vs WOK Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, WOK has a market cap of 6.8K. Regarding current trading prices, LMAT is priced at $110.75, while WOK trades at $1.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas WOK's P/E ratio is N/A. In terms of profitability, LMAT's ROE is +0.16%, compared to WOK's ROE of -0.07%. Regarding short-term risk, LMAT is less volatile compared to WOK. This indicates potentially lower risk in terms of short-term price fluctuations for LMAT.Check WOK's competition here
LMAT vs ARTC Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, ARTC has a market cap of 0. Regarding current trading prices, LMAT is priced at $110.75, while ARTC trades at $0.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas ARTC's P/E ratio is N/A. In terms of profitability, LMAT's ROE is +0.16%, compared to ARTC's ROE of N/A. Regarding short-term risk, LMAT is more volatile compared to ARTC. This indicates potentially higher risk in terms of short-term price fluctuations for LMAT.Check ARTC's competition here
LMAT vs HRC Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, HRC has a market cap of 0. Regarding current trading prices, LMAT is priced at $110.75, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas HRC's P/E ratio is 41.92. In terms of profitability, LMAT's ROE is +0.16%, compared to HRC's ROE of +0.14%. Regarding short-term risk, LMAT is more volatile compared to HRC. This indicates potentially higher risk in terms of short-term price fluctuations for LMAT.Check HRC's competition here
LMAT vs APR Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, APR has a market cap of 0. Regarding current trading prices, LMAT is priced at $110.75, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas APR's P/E ratio is 22.59. In terms of profitability, LMAT's ROE is +0.16%, compared to APR's ROE of +9.81%. Regarding short-term risk, LMAT is more volatile compared to APR. This indicates potentially higher risk in terms of short-term price fluctuations for LMAT.Check APR's competition here
LMAT vs IIN Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, IIN has a market cap of 0. Regarding current trading prices, LMAT is priced at $110.75, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas IIN's P/E ratio is 226.45. In terms of profitability, LMAT's ROE is +0.16%, compared to IIN's ROE of -0.00%. Regarding short-term risk, LMAT is more volatile compared to IIN. This indicates potentially higher risk in terms of short-term price fluctuations for LMAT.Check IIN's competition here
LMAT vs ATRS Comparison March 2026
LMAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.5B. In comparison, ATRS has a market cap of 0. Regarding current trading prices, LMAT is priced at $110.75, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 43.95, whereas ATRS's P/E ratio is 14.95. In terms of profitability, LMAT's ROE is +0.16%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, LMAT is more volatile compared to ATRS. This indicates potentially higher risk in terms of short-term price fluctuations for LMAT.Check ATRS's competition here